Exchange: NASDAQ·Updated 11:36 AM EST

SGHT News

News
all
press releases
Sight Sciences (SGHT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Sight Sciences (SGHT) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks
Sight Sciences (SGHT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Sight Sciences (SGHT) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks
More News
Sight Sciences, Inc. (SGHT) Reports Q3 Loss, Tops Revenue Estimates
Sight Sciences (SGHT) delivered earnings and revenue surprises of 0.00% and +6.46%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Sight Sciences, Inc. (SGHT) Expected to Beat Earnings Estimates: Should You Buy?
Sight Sciences (SGHT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks
Why Is Sight Sciences Stock Gaining Thursday?
Sight Sciences (SGHT) stock jumped after H.C. Wainwright initiated coverage with a Buy rating and a $14 price target nearly 70% upside.read more...
Benzinga
GKOS Stock Surges 67% Year to Date: What's Driving the Rally?
Glaukos' iDose TR momentum and Epioxa launch are driving record growth, higher 2026 guidance and a broader ophthalmology platform.
Zacks
Sight Sciences Announces FDA Label Expansion For TearCare Dry Eye Therapy
(RTTNews) - Sight Sciences, Inc. (SGHT), an eyecare technology company, on Wednesday said the U.S. Food and Drug Administration has expanded the indications for its TearCare System, making it the first treatment for meibomian gland dysfunction or MGD specifically cleared to impro...
Nasdaq News: Markets
Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates
Sight Sciences (SGHT) delivered earnings and revenue surprises of +46.67% and +7.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Sight Sciences (SGHT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Sight Sciences (SGHT) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks
Integer (ITGR) Q2 Earnings and Revenues Top Estimates
Integer (ITGR) delivered earnings and revenue surprises of +15.94% and +2.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Integra LifeSciences (IART) Q2 Earnings Top Estimates
Integra (IART) delivered earnings and revenue surprises of +16.67% and -0.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.